Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
The advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In vitro transcription (IVT) is the synthesis of RNA molecules. Creative Biolabs produces CAR mRNAs with our proprietary production platform, ensuring the quality and expression efficiency. This product is anti-LunX scFv (XW-33)-28BBZ chimeric antigen receptor (CAR) mRNA which can be used for CAR expression in various immune cells.
Specific Inquiry
Add to Cart
CAR Information
Target Species
Human
Clone
XW-33
Host
Mouse
CAR Construction
scFv-CD28-41BB-CD3ζ
CAR Generation
Third
CAR Signaling Description
CD28 CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy. 41BB CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity. CD3ζ CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CAR mRNA Properties
Cap
Cap 1
PolyA
Segmented PolyA
Product Type
CAR IVT mRNA
Concentration
Lot specific
Buffer
1 mM Sodium citrate (pH 6.4)
Storage
Aliquot and store at -80°C. Avoid freeze/thaw cycles.
Handling
Thaw and work with mRNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.
mRNA Quality Control
OD260/280
PASS
Agarose Gel Mobility
PASS
IVT Vector Sequencing
PASS
IVT Vector Enzyme Digestion
PASS
mRNA Transfection Efficiency
PASS
CAR Expression after mRNA Transfection
PASS
Target Information
Target
LunX
Gene Name
BPIFA1
Full Name
BPI fold containing family A member 1
Introduction
This gene is the human homolog of murine plunc, and like the mouse gene, is specifically expressed in the upper airways and nasopharyngeal regions. The encoded antimicrobial protein displays antibacterial activity against Gram-negative bacteria. It is thought to be involved in inflammatory responses to irritants in the upper airways and may also serve as a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Multiple transcript variants resulting from alternative splicing in the 3' UTR have been detected, but the full-length nature of only three are known.
There are currently no customer reviews or questions for VivoCAR™ Anti-Human LunX (XW-33) h(41BB-CD28-CD3ζ) CAR IVT mRNA (XS-0822-YF4633). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.